

DR. ANDREW M. MOON (Orcid ID : 0000-0001-7163-2062)

DR. OREN K FIX (Orcid ID : 0000-0002-8570-9646)

Article type : Special Article

Title: Alcohol-Associated Liver Disease Before and After COVID-19 – An Overview and Call for Ongoing Investigation

Short Title: Effects of COVID-19 on ALD

Authors:

Andrew M. Moon MD, MPH¹, Brenda Curtis PhD, MsPH², Pranoti Mandrekar PhD³, Ashwani K. Singal MD, MS^{4,5}, Elizabeth C. Verna MD, MSc⁶, Oren K. Fix MD, MSc⁷

Affiliations:

- (1) Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC
- (2) National Institute on Drug Abuse Intramural Research Program, Baltimore, MD
- (3) Department of Medicine, University of Massachusetts Medical School, Worcester, MA
- (4) Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD
- (5) Division of Transplant Hepatology, Avera Transplant Institute, Sioux Falls, SD
- (6) Center for Liver Disease and Transplantation, Columbia University, New York, NY
- (7) Department of Medical Education and Clinical Sciences, Washington State University Elson S. Floyd College of Medicine, Spokane, WA

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/hep4.1747](https://doi.org/10.1002/hep4.1747)

This article is protected by copyright. All rights reserved

Author Contributions:

All authors approved the final version of this manuscript

Andrew M. Moon is the guarantor of this paper

AMM: Conceptualization, writing original draft, critical review and revision

BC: Writing original draft, critical review and revision

PM: Critical review and revision

AKS: Critical review and revision

ECV: Critical review and revision

OKF: Conceptualization, critical review and revision

Corresponding Author:

Andrew Moon, MD, MPH

130 Mason Farm Road

Bioinformatics Building CB# 7080

Chapel Hill, North Carolina 27599-7080

Phone: (919) 974-2516

Email: Andrew.Moon@unchealth.unc.edu

Grant Support: This research was supported in part by NIH grant T32 DK007634 (AMM). This research was supported in part by the Intramural Research Program of the NIH, NIDA.

Disclosures/Conflicts of Interest: The authors have no disclosures of conflicts of interest to report.

Manuscript Word Count: 2034

References/Word Count: 43/1205

Tables/Figures: 1/0

Abbreviations :

AAPC – average annual percentage change

ALD – alcohol-associated liver disease

AUD – alcohol use disorder

COVID-19 – Coronavirus Disease-2019

NIAAA – National Institute of Alcohol Abuse and Alcoholism

NIH – National Institutes of Health

MELD – model for end-stage liver disease

SARS CoV-2 – severe acute respiratory syndrome coronavirus 2

Abstract

The Coronavirus Disease-2019 (COVID-19) pandemic has exacted a heavy toll on patients with alcohol-associated liver disease (ALD) and alcohol use disorder (AUD). The collective burden of ALD and AUD was large and growing prior to the COVID-19 pandemic. There is accumulating evidence that this pandemic has had a large direct effect on these patients and is likely to produce indirect effects via delays in care, psychological strain, and increased alcohol use. Now a year into the pandemic, it is important that clinicians fully understand the effects of the COVID-19 pandemic on patients with ALD and AUD. To fill existing gaps in knowledge, the scientific community must set research priorities for patients with ALD regarding their risk of COVID-19, prevention/treatment of COVID-19, changes in alcohol use during the pandemic, best use of AUD treatments in the COVID-19 era, and downstream effects of this pandemic on ALD. *Conclusion:* The COVID-19 pandemic has already inflicted disproportionate harms on patients with ALD and ongoing, focused research efforts will be critical to better understand the direct and collateral effects of this pandemic on ALD.

Keywords: SARS-CoV-2; coronavirus; pandemic; AUD; ALD

Introduction

Coronavirus Disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection, has had important direct and indirect effects on patients with alcohol-associated liver disease (ALD). Prior to the COVID-19 pandemic, the global toll of ALD was sizable and COVID-19 has inflicted disproportionate negative effects on this population. Early data suggest that patients with chronic liver disease, and particularly those with ALD, may be at greater risk of mortality if infected by SARS-CoV-2 (1-3). Furthermore, the COVID-19 pandemic and resulting social and economic stressors have contributed to increased psychological strain for many individuals, including those with alcohol use disorder (AUD) and ALD. As a result, the pandemic is likely to enact collateral damage on this population via delays in care and increases in alcohol use. Changes in alcohol use patterns may lead to alcohol-associated hepatitis and liver-related mortality. At the current time, approximately a year since SARS-CoV-2 virus was first identified (4), it is important that we assess the effects of this pandemic on ALD patients and define research priorities needed to mitigate these effects.

Pre-COVID-19 ALD Burden

In the pre-COVID-19 era, the burden of AUD and ALD was large and growing. National data from the US show that the prevalence of AUD and high-risk drinking has increased in recent years (5). The diagnosis of alcohol-associated cirrhosis is on the rise (6) and there have been corresponding increases in liver transplantation from ALD and alcohol-associated hepatitis (7, 8). There have also been larger numbers of ALD-related hospitalizations (9) and inpatient costs attributable to ALD now total more than every other liver disease etiology combined (10, 11).

Based on national death certificate data, mortality from ALD is also on the rise (12). Of concern, the average annual percentage changes in mortality rates have been most pronounced among younger individuals and women. Average annual percentage change (AAPC) in mortality in women age 25-34 years was 6.07 (95% CI 2.95-9.28) compared to women age 65-74 with AAPC 1.81 (95% CI 0.92-2.71).

Alcohol cessation can arrest or even reverse ALD (13) and AUD treatment is associated with lower decompensation rates, readmission, and mortality in patients with alcohol-associated cirrhosis

(14-16). Before COVID-19, implementation of AUD counseling or pharmacotherapy was only used among 10-14% of patients with alcohol-associated cirrhosis (5, 14, 15). Furthermore, there are concerning sex-based disparities with lower utilization of AUD treatment in women. This may be due to attitudinal barriers, more perceived stigma, and conflicting family or child care responsibilities (14).

Outcomes of ALD Patients with COVID-19

There are many reasons why alcohol use and ALD may predispose to worse outcomes from COVID-19. First, alcohol use and associated liver disease disrupts the innate and adaptive immune systems by affecting the survival and function of immune cells important in mounting a defense against viral infections (17, 18). Second, chronic alcohol consumption is associated with an increased susceptibility to acute respiratory distress syndrome (19-21). This may be related to alcohol's direct effects on immune function in addition to alveolar epithelial dysfunction and decreased concentration of pulmonary antioxidants in individuals with chronic alcohol abuse (22). Third, patients with alcohol use disorder often have other comorbidities including metabolic syndrome, chronic kidney disease and tobacco use, which have been independently associated with severe COVID-19 outcomes (23-25).

While patients with cirrhosis do not appear to be at increased risk for SARS-CoV-2 acquisition (26), there is now some direct evidence that among patients with liver disease, those with ALD fare worse with COVID-19. Data from an international registry study that included 179 patients (24%) with ALD demonstrated that cirrhosis, and particularly decompensated cirrhosis, was associated with worse outcomes from COVID-19 (1). Furthermore, even adjusting for potential confounders including medical comorbidities, ALD etiology was associated with an increased risk of mortality in COVID-19. Similar findings were reported in a US multi-center study in which decompensated cirrhosis, hepatocellular carcinoma, and ALD were independent risk factors for mortality in patients with COVID-19 (2).

Changes in Alcohol Consumption Related to COVID-19

Effects of the COVID-19 pandemic unrelated to SARS-CoV-2 infection itself may prove to have the biggest effect on ALD patients. Undoubtedly COVID-19 will enact massive collateral damage via the effects of deferred care, medication non-adherence, increased consumption of food and more high-risk alcohol use (27, 28). The pathophysiology of ALD is complex but overall alcohol dose and pattern of consumption are both strongly implicated in the risk of ALD (29). Increased alcohol consumption during the COVID-19 pandemic therefore has the potential to lead to increased morbidity and mortality.

A number of COVID-19-related factors have the potential to increase alcohol use in patients with AUD or excess drinking. Factors that increase alcohol use may include adverse economic effects resulting from the COVID-19 pandemic, disruptions in work and education, psychosocial stressors associated with limitations on social gatherings, social isolation with decreased or lack of social support system, and shifts in alcohol consumption from bars/restaurants to at-home use (30).

Epidemiologic and marketing data during early days in the pandemic showed a spike in alcohol use in the general population. In April 2020, online sales of alcohol in the US were up 477% and brick-and-mortar sales were up 26% compared to sales from the year prior (31). Post-pandemic increases in alcohol purchases were most pronounced in younger adults, households with children younger than 18 years, and ethnic minorities (32). Similar findings were demonstrated in Canada, where there was a 38% relative increase in monthly alcohol sales in March 2020 compared to March 2019 (33). Online sales may have lower cost per unit of alcohol, which could lead to increased consumption. Additionally, sales of larger packs of alcohol including boxes of wine, large volume (e.g. 1.75 liter) liquor bottles, and 30-packs of beer have all increased compared to previous years (31). Emerging data suggest that individuals, and particularly females, are engaging in an increased frequency of alcohol consumption and binge drinking (34, 35). In sum these data imply that increasing trends in alcohol sales are translating to increased alcohol consumption and are not attributable to increased alcohol stockpiling alone.

Some concerning trends have also been shown in individuals with AUD. Researchers in the United Kingdom identified individuals with pre-existing alcohol disorders and performed a cross-sectional telephone survey two months after their national lockdown (36). Of 182 participants, 24% reported an increase in their alcohol use, consuming an average of 48.8 units of alcohol (approx. 5.5

bottles of wine, 1.5 bottles of spirits, or 16 pints of beer) per week after lockdown. In contrast, only 19% reported a decrease in alcohol intake.

There are already some early signs that accelerations in alcohol-associated health effects among women may worsen in the COVID-19 era. During the pandemic, women have taken on a disproportionate amount of work at home and have borne a higher economic burden than men (37). There are some early data suggesting that this may be leading to larger increases in alcohol use and alcohol-associated health effects in women (38). As mentioned previously, there is lower utilization of AUD treatment among women (14). It is unclear how this may change in the COVID-19 era given expanded options for AUD treatment, including virtual counseling and online Alcoholics Anonymous meetings.

Downstream Effects of COVID-19 on ALD Patients

Given the association between alcohol use and poor outcomes in ALD, COVID-19-related changes in alcohol consumption have the potential to lead to direct alcohol-associated health effects, including alcohol-associated hepatitis and liver-related mortality. Furthermore, depending on program requirements for pre-transplant abstinence, alcohol relapses could lead to decreased transplant referrals and waitlist drop-off in pre-liver transplant patients. While it is still too early to fully assess the effect of changes in alcohol consumption patterns in the wake of the COVID-19 pandemic, there are some early data that are concerning.

In the spring of 2020, as the US COVID-19 outbreak was beginning, there were some signs that cirrhosis patients were delaying care. Data from the National Veterans Affairs healthcare system show a rapid drop off in cirrhosis admissions beginning in March of 2020 compared to historic data from the prior year (39). Patients admitted later had higher model for end-stage liver disease (MELD) scores, suggesting that only the sickest patients were coming in for care. In addition, there was a very slight increase in the proportion of cirrhosis-related hospitalizations among patients with ALD compared to other etiologies.

Increases in alcohol consumption in the COVID-19 era also have the potential to contribute directly to the burden of alcohol-associated liver disease. Some have raised concern that increased harmful drinking in the wake of COVID-19 could contribute to an increasing incidence of alcohol-

associated hepatitis (30). Early anecdotal reports that alcohol-associated hospitalizations have increased (40) are now corroborated by a single-center study demonstrating an increasing number of hospitalizations and liver transplants among patients with ALD in the COVID-19 era (41).

Changes in alcohol consumption in the COVID-19 era could also have huge implications on patients listed for transplantation. In the previously mentioned telephone survey conducted in the United Kingdom (36), 17% of patients who were abstinent prior to the lockdown experienced a relapse during lockdown. If similar patterns of alcohol relapse are occurring in patients listed for transplant this could negatively impact the listing status of many patients.

Call for Ongoing Investigation of COVID-19 and ALD

To mitigate the downstream effects of the COVID-19 pandemic on patients with ALD, there is an urgent unmet need to identify, investigate, and address clinically-important questions relevant to this population (Table 1). These research priorities should fit within the larger framework of ongoing strategies to address the growing burden of ALD and AUD (42). Specific areas that deserve further attention include COVID-19 outcomes in ALD, with and without cirrhosis; COVID-19 treatments for patients with chronic liver disease and ALD; safety and efficacy of the COVID-19 vaccine in patients with ALD; the effects of the COVID-19 pandemic on alcohol use patterns; the efficacy of remote AUD counseling such as digital or virtual technology and use of telemedicine; and changes in the incidence of alcohol-associated health effects including alcohol-associated hepatitis, alcohol-associated-acute-on-chronic liver failure, alcohol-associated cirrhosis, and decompensations in patients with established cirrhosis. Furthermore, additional discussion of transplant listing policies for patients who relapse during the pandemic is critical given the unique and challenging stressors related to the COVID-19 pandemic.

Such research efforts have the potential to inform the clinical care of patients with ALD including tailored COVID-19 treatment guidelines and guidance on the optimal use of corticosteroids in patients with severe alcohol-associated hepatitis infected with SARS-CoV-2. This work could also have immediate policy implications including informing vaccination strategies and recommendations regarding shielding (i.e. minimizing all face-to-face contact for extremely clinically vulnerable) for patients with ALD and better understanding factors that may contribute to increased alcohol use.

Additionally, these efforts could explore potential disparities in alcohol consumption and ALD by sex and race/ethnicity, determine care delivery models best suited to address AUD, and inform transplant listing decisions for patients who experience relapse during the COVID-19 pandemic.

The National Institutes of Health (NIH)/National Institute on Alcohol Abuse and Alcoholism (NIAAA) have prioritized investigation of alcohol use in the era of COVID-19. There are new Requests for Applications (RFA) for grants that address the relationship between alcohol consumption and outcomes of COVID-19, including the impact of alcohol misuse on COVID-19 incidence and severity and effects of pandemic-related restrictions on high-risk drinking and AUD (43).

Conclusions

In conclusion, prior to COVID-19, alcohol-associated liver disease had a massive and growing burden. Early in the COVID-19 pandemic, we observed worse outcomes from COVID-19 infections among patients with ALD. There has also been significant collateral damage related to the pandemic, including psychosocial strain and limited access to healthcare, which may lead to more high-risk drinking. Increases in the frequency and amount of alcohol intake have the potential to increase morbidity and mortality in patients with ALD. There are already some early signs that ALD patients are experiencing poor outcomes in the wake of COVID-19, including delays in care and an increase in alcohol-associated hepatitis. Furthermore, an increase in relapses or an inability to confirm sobriety in the COVID-19 era has the potential to lead to transplant listing challenges for many patients. Ongoing investigation is critical to better understand the collateral damage on patients with ALD.

References

1. Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. *J Hepatol* 2020.
2. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, et al. Predictors of Outcomes of COVID-19 in Patients with Chronic Liver Disease: US Multi-center Study. *Clin Gastroenterol Hepatol* 2020.
3. Marjot T, Webb GJ, Barritt ASt, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. *Nat Rev Gastroenterol Hepatol* 2021.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323:1061-1069.
5. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, et al. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry* 2017;74:911-923.
6. Mellinger JL, Shedden K, Winder GS, Tapper E, Adams M, Fontana RJ, Volk ML, et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. *Hepatology* 2018;68:872-882.
7. Cholankeril G, Ahmed A. Alcoholic Liver Disease Replaces Hepatitis C Virus Infection as the Leading Indication for Liver Transplantation in the United States. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association* 2018;16:1356-1358.
8. Lee BP, Vittinghoff E, Dodge JL, Cullaro G, Terrault NA. National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States. *JAMA Intern Med* 2019;179:340-348.
9. Shirazi F, Singal AK, Wong RJ. Alcohol-associated Cirrhosis and Alcoholic Hepatitis Hospitalization Trends in the United States. *J Clin Gastroenterol* 2021;55:174-179.

10. Barritt ASt, Jiang Y, Schmidt M, Hayashi PH, Bataller R. Charges for Alcoholic Cirrhosis Exceed All Other Etiologies of Cirrhosis Combined: A National and State Inpatient Survey Analysis. *Dig Dis Sci* 2019;64:1460-1469.
11. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. *JAMA Netw Open* 2020;3:e201997.
12. Moon AM, Yang JY, Barritt ASt, Bataller R, Peery AF. Rising Mortality From Alcohol-Associated Liver Disease in the United States in the 21st Century. *Am J Gastroenterol* 2020;115:79-87.
13. Thiele M, Rausch V, Fluhr G, Kjaergaard M, Piecha F, Mueller J, Straub BK, et al. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. *J Hepatol* 2018;68:1025-1032.
14. Mellinger JL, Fernandez A, Shedden K, Winder GS, Fontana RJ, Volk ML, Blow FC, et al. Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis. *Alcohol Clin Exp Res* 2019;43:334-341.
15. Rogal S, Youk A, Zhang H, Gellad WF, Fine MJ, Good CB, Chartier M, et al. Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis. *Hepatology* 2020;71:2080-2092.
16. Peeraphatdit TB, Kamath PS, Karpyak VM, Davis B, Desai V, Liangpunsakul S, Sanyal A, et al. Alcohol Rehabilitation Within 30 Days of Hospital Discharge Is Associated With Reduced Readmission, Relapse, and Death in Patients With Alcoholic Hepatitis. *Clin Gastroenterol Hepatol* 2020;18:477-485 e475.
17. Szabo G, Saha B. Alcohol's Effect on Host Defense. *Alcohol Res* 2015;37:159-170.
18. Takeuchi O, Akira S. Innate immunity to virus infection. *Immunol Rev* 2009;227:75-86.
19. Simou E, Leonardi-Bee J, Britton J. The Effect of Alcohol Consumption on the Risk of ARDS: A Systematic Review and Meta-Analysis. *Chest* 2018;154:58-68.
20. Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. *JAMA* 1996;275:50-54.
21. Moss M, Parsons PE, Steinberg KP, Hudson LD, Guidot DM, Burnham EL, Eaton S, et al. Chronic alcohol abuse is associated with an increased incidence of acute respiratory distress

syndrome and severity of multiple organ dysfunction in patients with septic shock. *Crit Care Med* 2003;31:869-877.

22. Boe DM, Vandivier RW, Burnham EL, Moss M. Alcohol abuse and pulmonary disease. *J Leukoc Biol* 2009;86:1097-1104.

23. Fan AZ, Russell M, Naimi T, Li Y, Liao Y, Jiles R, Mokdad AH. Patterns of alcohol consumption and the metabolic syndrome. *J Clin Endocrinol Metab* 2008;93:3833-3838.

24. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. *Am J Epidemiol* 2006;164:263-271.

25. DiMartini A, Javed L, Russell S, Dew MA, Fitzgerald MG, Jain A, Fung J. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. *Liver Transpl* 2005;11:679-683.

26. Ioannou GN, Liang PS, Locke E, Green P, Berry K, O'Hare AM, Shah JA, et al. Cirrhosis and SARS-CoV-2 infection in US Veterans: risk of infection, hospitalization, ventilation and mortality. *Hepatology*;n/a.

27. Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. *J Hepatol* 2020;73:441-445.

28. Stanfield D, Lucey MR. The Heightened Risk of Fatty Liver Disorders in the Time of COVID-19. *Mayo Clin Proc* 2020;95:2580-2581.

29. Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases. *Hepatology* 2020;71:306-333.

30. Da BL, Im GY, Schiano TD. Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease. *Hepatology* 2020;72:1102-1108.

31. Nielsen. Rebalancing the 'COVID-19' Effect on Alcohol Sales.

<https://www.nielsen.com/us/en/insights/article/2020/rebalancing-the-covid-19-effect-on-alcohol-sales/#:~:text=A%20Nielsen%20investigation%20of%20the,of%20closed%20bars%20and%20restau>rants. Accessed January 4, 2021.

32. Lee BP, Dodge JL, Leventhal A, Terrault NA. Retail Alcohol and Tobacco Sales During COVID-19. *Ann Intern Med* 2021.

33. Zipursky JS, Stall NM, Silverstein WK, Huang Q, Chau J, Hillmer MP, Redelmeier DA. Alcohol Sales and Alcohol-Related Emergencies During the COVID-19 Pandemic. *Ann Intern Med* 2021.
34. Pollard MS, Tucker JS, Green HD, Jr. Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. *JAMA Netw Open* 2020;3:e2022942.
35. Grossman ER, Benjamin-Neelon SE, Sonnenschein S. Alcohol Consumption during the COVID-19 Pandemic: A Cross-Sectional Survey of US Adults. *Int J Environ Res Public Health* 2020;17.
36. Kim JU, Majid A, Judge R, Crook P, Nathwani R, Selvapatt N, Lovendoski J, et al. Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder. *Lancet Gastroenterol Hepatol* 2020;5:886-887.
37. Wenham C, Smith J, Morgan R, Gender, Group C-W. COVID-19: the gendered impacts of the outbreak. *Lancet* 2020;395:846-848.
38. Rehm J, Kilian C, Ferreira-Borges C, Jernigan D, Monteiro M, Parry CDH, Sanchez ZM, et al. Alcohol use in times of the COVID 19: Implications for monitoring and policy. *Drug Alcohol Rev* 2020;39:301-304.
39. Mahmud N, Hubbard RA, Kaplan DE, Serper M. Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study. *Gastroenterology* 2020;159:1134-1136 e1133.
40. Hein I. Alcohol Abuse Agitated by COVID-19 Stirring Liver Concerns. <https://www.medscape.com/viewarticle/930039>. Accessed January 4, 2021.
41. Rutledge SM, Schiano TD, Florman S, Im GY. COVID-19 Aftershocks on Alcohol-associated Liver Disease: An Early Cross-Sectional Report from the U.S. Epicenter. *Hepatology Communications* 2021.
42. Asrani SK, Mellinger J, Arab JP, Shah VH. Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action. *Hepatology* 2020.
43. National Institutes of Health. SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed). <https://grants.nih.gov/grants/guide/rfa-files/RFA-AA-21-002.html>. Accessed March 30, 2021.

Table 1. Research Priorities for COVID-19 and Alcohol-Associated Liver Disease (ALD)

Research Priority	Clinical/Policy Implications
<i>Risk and Outcomes of COVID-19 in ALD</i>	
Incidence of COVID-19 infection in ALD	- Inform recommendations regarding shielding (i.e. avoidance of all person-to-person contact in extremely vulnerable) for patients with ALD
COVID-19 outcomes in patients with ALD	- Better understanding of relative influences of alcohol use and underlying liver disease on COVID-19 outcomes - Tailored clinical care guidelines for ALD patients
Treatment of alcohol-associated hepatitis and COVID-19	- Determine the optimal use of corticosteroids in patients with alcohol-associated hepatitis and COVID-19
<i>COVID-19 Therapies/Vaccination</i>	
Efficacy of COVID-19 therapies in ALD	- Provide clinical guidance for SARS-CoV-2 infections in patients with ALD
Risks of COVID-19 therapies in ALD	- Provide clinical guidance for SARS-CoV-2 infections in patients with ALD - Better inform patients on expected risks of these therapies
Safety and efficacy of COVID-19 vaccinations in ALD	- Magnitude/duration of vaccine response - Effect of liver disease severity on vaccine response - Need for additional booster doses for adequate immunologic response and protection - Risk of liver injury
<i>Alcohol Use during COVID-19 Pandemic</i>	
Patterns of alcohol consumption during the COVID-19 pandemic	- Determine if increased online sales of alcohol translate into increases in overall consumption - Inform policy that could reduce harms from alcohol use during the pandemic
Factors associated with unhealthy alcohol use during COVID-19	Ascertain policy priorities (e.g. alcohol pricing, depression/anxiety treatment, unemployment benefits) to address alcohol use disorder during COVID-19
Disparities in alcohol consumption by sex and race/ethnicity	- Identify high-risk populations who may benefit from targeted interventions - Assess effects of concurrent non-COVID-19-related stressors including social unrest because of racial disparities and polarizing politics

<i>Alcohol Use Disorder Treatments during COVID-19 Pandemic</i>	
Efficacy of remote alcohol use counseling and monitoring	<ul style="list-style-type: none"> - Inform reimbursement policy in the post-COVID-19 era - Assess benefits of continuing remote alcohol use treatment for select patients - Determine care delivery models (e.g. telemedicine, video counseling) that are best suited for alcohol use disorder
<i>Downstream Effects of COVID-19 on ALD</i>	
Incidence of alcohol-associated hepatitis, alcohol-associated-acute-on-chronic liver failure and cirrhosis	<ul style="list-style-type: none"> - Address disparities by sex and race/ethnicity - Better account for hepatology care needs in the post-COVID-19 era - Expansion in alcohol use disorder counseling resources
Transplant considerations for ALD patients who relapsed	<ul style="list-style-type: none"> - Inform transplant listing policy decisions for patients who experience relapse during COVID-19 pandemic